US investment curbs could complicate Chinese biotech expansion
Proposed US outbound investment restrictions may disrupt deal structures for Chinese biotech firms, complicating their global expansion efforts.
Proposed US outbound investment restrictions may disrupt deal structures for Chinese biotech firms, complicating their global expansion efforts.